Patents Issued in April 21, 2020
-
Patent number: 10626393Abstract: The present invention provides lipid particles comprising therapeutic nucleic acids such as gRNA that target gene expression.Type: GrantFiled: June 6, 2016Date of Patent: April 21, 2020Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Amy C. H. Lee, Nicholas D. Weber
-
Patent number: 10626394Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: Massachusetts Institute of TechnologyInventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl
-
Patent number: 10626395Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.Type: GrantFiled: September 18, 2017Date of Patent: April 21, 2020Assignees: The General Hospital Corporation, Aalborg UniversityInventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
-
Patent number: 10626396Abstract: A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.Type: GrantFiled: May 22, 2018Date of Patent: April 21, 2020Assignee: Sarepta Therapeutics, Inc.Inventors: Patrick L. Iversen, Dwight D. Weller, Alan P. Timmins
-
Patent number: 10626397Abstract: A method of inhibiting the growth of cancer stem cells, including administering an effective amount of a protein kinase D1 expression or activity inhibitor as an active ingredient to a subject having cancer is provided. Further, a method of treating cancer, including administering an effective amount of a protein kinase D1 expression or activity inhibitor, and antitumor agent as active ingredients to a subject having cancer is provided. Further, a method for measuring expression or activity of protein kinase D1 for providing information of breast cancer prognosis, including a step of measuring expression or activity of protein kinase D1 in cells or tissues isolated from a subject is provided.Type: GrantFiled: June 8, 2017Date of Patent: April 21, 2020Assignee: SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Jong Hoon Park, Do Yeon Kim, Eun Young Park, Kyung-Hee Chun, Eun Ji Lee, Eun Sun Chang, Hyeok-Gu Kang
-
Patent number: 10626398Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.Type: GrantFiled: January 21, 2019Date of Patent: April 21, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Tod Woolf, Margaret Taylor
-
Patent number: 10626399Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.Type: GrantFiled: January 6, 2017Date of Patent: April 21, 2020Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
-
Patent number: 10626400Abstract: The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.Type: GrantFiled: July 4, 2014Date of Patent: April 21, 2020Assignee: BioNTech AGInventor: Steve Pascolo
-
Patent number: 10626401Abstract: The invention relates to non-CpG single-stranded oligonucleotides (ssONs) for use in the treatment or prophylaxis of disorders of the skin and/or subcutaneous tissue, including pruritus, in a suitable formulation or in combination with other immunomodulatory treatments. The said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2?-O-Methyl modifications.Type: GrantFiled: June 14, 2016Date of Patent: April 21, 2020Assignee: TIRMED PHARMA ABInventors: Anna-Lena Spetz, Peter Jarver, Annette Skold
-
Patent number: 10626402Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: March 7, 2019Date of Patent: April 21, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn MacDonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Patent number: 10626403Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.Type: GrantFiled: October 1, 2018Date of Patent: April 21, 2020Assignee: Aviex Textnologies LLCInventor: David Gordon Bermudes
-
Patent number: 10626404Abstract: The present invention provides information on a mutant xylose isomerase gene and a mutant protein with which it is possible to impart high xylose metabolic capacity to budding yeast. Also provided is a yeast strain having the mutant xylose isomerase gene. Additionally provided is an efficient method for producing a useful substance using the yeast strain. The present invention provides mutant Clostridium-phytofermentans-derived xylose isomerase (CpXI) having high xylose metabolic activity, the CpXI comprising an amino acid sequence corresponding to an amino acid sequence in which the number 63 threonine of SEQ ID NO: 11 of CpXI is substituted by isoleucine, leucine, glycine, or histidine and/or the number 162 valine is substituted by alanine.Type: GrantFiled: March 24, 2017Date of Patent: April 21, 2020Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Taisuke Seike, Kazuhiro Fujimori, Yosuke Kobayashi, Takehiko Sahara, Satoru Ohgiya, Yoichi Kamagata
-
Patent number: 10626405Abstract: To provide a base sequence for protein expression that can increase the yield of protein such as diastatic enzyme by further activating a promoter of a particular gene. A base sequence 1 for protein expression includes: a gene 3 encoding protein 2; a promoter 4 of the gene 3, the promoter being linked upstream of the gene 3; and a cis element 5 whose activity is improved by an artificial transcription factor 6, the cis element being linked further upstream of the promoter 4. The cis element 5 is represented by SEQ ID NO: 1.Type: GrantFiled: July 15, 2016Date of Patent: April 21, 2020Assignee: Honda Motor Co., Ltd.Inventors: Satoru Shinkawa, Shigenobu Mitsuzawa, Maiko Tanaka, Masayuki Machida, Hiroko Hagiwara, Hideaki Koike, Mahoko Kuninaga
-
Patent number: 10626406Abstract: The invention relates to the field of plant improvement, in particular of the improvement of yield for plants, by using a transgene containing an root-specific promoter driving expression of a MYB-related protein.Type: GrantFiled: July 29, 2016Date of Patent: April 21, 2020Assignee: GENOPLANTE-VALORInventors: François Torney, Jérôme Martin, Stéphane Lafarge
-
Patent number: 10626407Abstract: A method of modifying the amount of at least one biochemical component in a plant comprising expressing Qua-Quine Starch (QQS) in the plant, the wild-type of which does not express QQS; a transgenic plant, or part thereof, which comprises and expresses QQS as a transgene and in which the amount of at least one biochemical component is modified; a tissue culture of regenerable cells of the transgenic plant; a vector comprising a nucleotide sequence, which encodes the coding sequence of QQS, operably linked to a non-native promoter, which promotes expression of the nucleotide sequence in a plant, which is other than Arabidopsis; and a method of producing a food or industrial product from a plant.Type: GrantFiled: November 21, 2017Date of Patent: April 21, 2020Assignee: Iowa State University Research Foundation, Inc.Inventors: Ling Li, Eve Syrkin Wurtele
-
Patent number: 10626408Abstract: A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant.Type: GrantFiled: October 3, 2017Date of Patent: April 21, 2020Assignee: CollPlant Ltd.Inventors: Oded Shoseyov, Hanan Stein
-
Patent number: 10626409Abstract: Provided herein are genetic markers and a coding sequence associated with a low- or ultra-low anatabine trait in tobacco.Type: GrantFiled: July 8, 2015Date of Patent: April 21, 2020Assignee: ALTRIA CLIENT SERVICES LLCInventors: Chengalrayan Kudithipudi, Alec J. Hayes, Robert Frank Hart, III, Yanxin Shen, Jesse Frederick, Dongmei Xu
-
Patent number: 10626410Abstract: Isolated polynucleotides and polypeptides, and recombinant DNA constructs useful for conferring improved nitrogen use efficiency and/or drought stress tolerance; compositions (such as plants or seeds) comprising these recombinant DNA constructs; and methods utilizing these recombinant DNA constructs are disclosed. The recombinant DNA constructs comprise a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotides encode abiotic stress tolerance polypeptides.Type: GrantFiled: January 29, 2019Date of Patent: April 21, 2020Inventors: Guihua Lu, Yang Gao, Cong Li, Junhua Liu, Guanfan Mao, Wei Wang, Xiping Wang, Changgui Wang
-
Patent number: 10626411Abstract: The present disclosure relates to a gene sequence Cry1Ab/Cry1AcZM, an expression cassette containing the gene, an expression vector, a host cell and the use thereof in plant breeding. The protein encoded by an insect-resistant gene according to the disclosure can be expressed in a monocotyledonous plant and further used for culturing an insect-resistant transgenic monocotyledonous plant harboring transgenes Cry1Ab/Cry1AcZM. Bioassay tests prove that the modified and synthesized gene sequence Cry1Ab/Cry1AcZM and the expression product of the constructed vector according to the disclosure have a killing effect on lepidopteran pests.Type: GrantFiled: July 22, 2016Date of Patent: April 21, 2020Assignee: China National Seed Group Corporation, Ltd.Inventors: Bolin Liu, Chao Tan, Qianqian Yang, Jieting Xu, Qin Wen, Long Qiu, Chonglie Ma, Wanggen Zhang
-
Patent number: 10626412Abstract: A newly identified protein that is encoded by a polynucleotide sequence associated with cytoplasmic male sterility restorer activity (Rf3) is described. The cytoplasmic male sterility restorer gene can be inserted through breeding introgression into plant genomes to restore cytoplasmic male sterility in plants. Further applications of the newly identified polynucleotide sequence associated with cytoplasmic male sterility restorer activity include a mutation (rf3) which results in cytoplasmic male sterility. The cytoplasmic male sterility restorer gene can be inserted through breeding introgression into plant genomes to result in cytoplasmic male sterility in plants. Methods for detecting the cytoplasmic male sterility restorer (Rf3) and the cytoplasmic male sterility (rf3) gene sequences are further described.Type: GrantFiled: February 2, 2018Date of Patent: April 21, 2020Assignee: Dow AgroSciences LLCInventors: Ruihua Ren, Bruce A. Nagel, Liang Ye, Yanxin Star Gao, Ryan Gibson, Sushmitha Paulraj, Tyler Mansfield, Jafar Mammadov, Siva P. Kumpatla, Steven A. Thompson
-
Patent number: 10626413Abstract: The present invention provides a nucleic acid vector referred to as pVec constructed through molecular biotechnologies. pVec contains CMV enhancer/promoter, T7 promoter, 5?UTR, MCS, 3?UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc. So pVec can be used as a vector for both DNA vaccines or therapeutic drugs and mRNA vaccines or mRNA therapeutic drugs. The 5?UTR, 3?UTR and poly A (120A)-TTATT of pVec can be added to the 5? and 3? ends of the in vitro transcribed mRNA respectively and further stabilize the transcribed mRNA. The present invention also provides the constructed pVec-GM-CSF, pVec-hIL-12 and pVAX1-hIL-12, which are used for evaluating the benefits of pVec.Type: GrantFiled: January 15, 2016Date of Patent: April 21, 2020Inventor: Enyu Ding
-
Patent number: 10626414Abstract: The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.Type: GrantFiled: September 18, 2017Date of Patent: April 21, 2020Inventors: Andreas Gallei, Alice Mundt, Veljko Nikolin
-
Patent number: 10626415Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: The Trustees of the University of PennsylvaniaInventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
-
Patent number: 10626416Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.Type: GrantFiled: August 22, 2019Date of Patent: April 21, 2020Assignee: Inscripta, Inc.Inventors: Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb
-
Patent number: 10626417Abstract: A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.Type: GrantFiled: October 11, 2016Date of Patent: April 21, 2020Inventors: David B. Avner, James Kehler, Sven Bocklandt
-
Patent number: 10626418Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: GrantFiled: July 24, 2018Date of Patent: April 21, 2020Assignee: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 10626419Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: November 27, 2018Date of Patent: April 21, 2020Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 10626420Abstract: The invention features methods for producing isoprene from cultured cells. The invention also provides compositions that include these cultured cells.Type: GrantFiled: January 17, 2018Date of Patent: April 21, 2020Assignees: Danisco US Inc., The Goodyear Tire & Rubber CompanyInventors: Marguerite A. Cervin, Gopal K. Chotani, Frank J. Feher, Richard La Duca, Joseph C. McAuliffe, Andrei Miasnikov, Caroline M. Peres, Aaron S. Puhala, Karl J. Sanford, Fernando Valle, Gregory M. Whited
-
Patent number: 10626421Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.Type: GrantFiled: April 21, 2015Date of Patent: April 21, 2020Assignees: FONDATION MEDITERRANEE INFECTION FACULTÉ DE MÉDECINE, UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Didier Raoult, Saber Khelaifia, Michel Drancourt
-
Patent number: 10626422Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway (MMP) that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 1,4-butanediol (BDO). Also provided herein are methods for using such an organism to produce BDO.Type: GrantFiled: August 27, 2013Date of Patent: April 21, 2020Assignee: Genomatica, Inc.Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
-
Patent number: 10626423Abstract: A non-naturally occurring microorganism having a 1,3-BDO pathway is provided. The microorganism expresses at least one of the following 1,3-BDO pathway enzymes: an aldolase that catalyzes condensation of two acetaldehydes to produce 3-hydroxybutanal; and an aldo-ketoreductase, oxidoreductase, aldehyde reductase or alcohol dehydrogenase that reduces 3-hydroxybutanal to 1,3-BDO. The organism may further express one or more enzymes for producing acetaldehyde. A biosynthetic process involves condensing two acetaldehyde molecules to 3-hydroxybutanal using an enzyme from class aldolases; and selectively reducing 3-hydroxybutanal to 1,3-BDO using an enzyme belonging to the class aldo-ketoreductase, oxidoreductase, aldehyde reductase or alcohol dehydrogenase. The process can further include producing acetaldehyde by a biosynthetic method.Type: GrantFiled: July 21, 2016Date of Patent: April 21, 2020Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Radhakrishnan Mahadevan, Alexander Yakunin, Pratish Gawand, Kayla Nemr
-
Patent number: 10626424Abstract: Recombinant microbial cells comprising an engineered LCDA production pathway that comprises at least one up-regulated long-chain acyl-CoA synthetase (ACoS) are disclosed. These recombinant microbial cells are capable of producing one or more long-chain dicarboxylic acid (LCDA) products from a long-chain fatty acid-comprising substrate. Methods of using recombinant microbial cells to produce LCDAs are also disclosed.Type: GrantFiled: July 20, 2016Date of Patent: April 21, 2020Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLCInventors: Quinn Qun Zhu, Xiaochun Fan, Seung-Pyo Hong, Despina Boughioukou, Dongming Xie, Himanshu H. Dhamankar
-
Patent number: 10626425Abstract: The present invention relates to a microorganism for producing diamine, in which activity of a protein having an amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having 55% or higher sequence homology with SEQ ID NO: 6 is introduced or enhanced, and a method of producing diamine using the same.Type: GrantFiled: January 4, 2019Date of Patent: April 21, 2020Assignee: CJ CHEILJEDANG CORPORATIONInventors: Kyoung Min Lee, Su Jin Park, Hee Kyoung Jung, Young Lyeol Yang, Hong Xian Li, Hye Won Um
-
Patent number: 10626426Abstract: The present invention relates to a microorganism of the genus Corynebacterium having an ability to produce L-arginine, and a method of producing L-arginine using the same.Type: GrantFiled: October 13, 2015Date of Patent: April 21, 2020Assignee: CJ CHEILJEDANG CORPORATIONInventors: Hyun Ae Bae, Han Hyoung Lee, Min Gyeong Kang, Jong Hyun Kim, Hye Won Kim
-
Patent number: 10626427Abstract: The present invention relates to a mutated protein of FMO derived from Celeribacter sp. and a gene encoding the same, a vector comprising the gene, a recombinant cell transformed by the vector, a composition for producing indigo comprising them, and a method for increasing indigo production in the recombinant cell using the transformed recombinant cell.Type: GrantFiled: April 22, 2019Date of Patent: April 21, 2020Assignee: GYEONGBUK INSTITUTE FOR MARINE BIOINDUSTRYInventors: Jung Hee Woo, Hae Seon Kim, Nyun-Ho Park
-
Patent number: 10626428Abstract: The present invention relates to the field of poly- and oligosaccharides and their dietary effects. In particular it relates to a method of producing a branched ?-glucan. Further aspects of the invention are a branched ?-glucan comprising alternating ?(1?4) and ?(1?6) glucosidic linkages and having ?(1?4,6) branching points, a food composition, and the use of an ?-glucanotransferase enzyme for reducing the digestible carbohydrates of a starch containing food material.Type: GrantFiled: September 12, 2016Date of Patent: April 21, 2020Assignee: Societe des Produits Nestle S.A.Inventors: Joana Gangoiti Munecas, Sander Sebastiaan Van Leeuwen, Lubbert Dijkhuizen, Christina Vafeiadi, Lisa Lamothe
-
Patent number: 10626429Abstract: The present invention relates to methods of joining two or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro, wherein the distal region of the first DNA molecule and the proximal region of the second DNA molecule of each pair share a region of sequence identity. The method allows the joining of a large number of DNA fragments, in a predetermined order and orientation, without the use of restriction enzymes. It can be used, e.g., to join synthetically produced sub-fragments of a gene or genome of interest. Kits for performing the method are also disclosed. The methods of joining DNA molecules may be used to generate combinatorial libraries useful to generate, for example, optimal protein expression through codon optimization, gene optimization, and pathway optimization.Type: GrantFiled: July 31, 2019Date of Patent: April 21, 2020Assignee: SGI-DNA, Inc.Inventors: Daniel G. Gibson, Hamilton O. Smith, Clyde A. Hutchison, Lei Young, J. Craig Venter
-
Patent number: 10626430Abstract: The present invention provides a method for preparing a mogroside having no ?-1,6-glucoside bond comprising the step of reacting glycosidase ASBGL2, AOBGL2, AOBGL1, ASBGL1, or a variant thereof with a mogroside having at least one ?-1,6-glucoside bond, thereby cleaving said ?-1,6-glucoside bond.Type: GrantFiled: January 19, 2016Date of Patent: April 21, 2020Assignee: SUNTORY HOLDINGS LIMITEDInventors: Misa Ochiai, Eiichiro Ono
-
Patent number: 10626431Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.Type: GrantFiled: June 30, 2016Date of Patent: April 21, 2020Assignee: OCTAPHARMA AGInventor: Stefan Winge
-
Patent number: 10626432Abstract: A composition is provided. The composition comprises an enzyme and a ruthenium- or osmium-based electron transfer agent, wherein the ruthenium- or osmium-based electron transfer agent is a complex [M(A)x(B)y](X)n wherein M is ruthenium or osmium; A is an amine ligand; each B is a ligand different to A; x is an integer selected from 1 to 5; y is an integer selected from 1 to 5; x+y is 6 or 8; n is an integer selected from 1 to 6; and X is any suitable counterion.Type: GrantFiled: April 28, 2016Date of Patent: April 21, 2020Assignee: INSIDE BIOMETRICS INTERNATIONAL LIMITEDInventors: Marco Cardosi, Stephanie Kirkwood
-
Patent number: 10626433Abstract: The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor.Type: GrantFiled: March 21, 2018Date of Patent: April 21, 2020Assignees: Ikeda Food Research Co., Ltd., PHC CorporationInventors: Hironori Omura, Hirokazu Sanada, Takako Yada, Ayaka Atsumi, Tetsunari Morita, Emi Ishimaru
-
Patent number: 10626434Abstract: The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor.Type: GrantFiled: September 28, 2018Date of Patent: April 21, 2020Assignees: Ikeda Food Research Co., Ltd., PHC CorporationInventors: Hironori Omura, Hirokazu Sanada, Takako Yada, Ayaka Atsumi, Tetsunari Morita, Emi Ishimaru
-
Patent number: 10626435Abstract: Nanofluidic devices and methods of the invention are capable of autonomously isolating individual microbial cells using constrictive channels and growing monocultures of the cells for automated characterization of their biochemical properties and interactions with mammalian cells. Single microbial cells, such as bacterial cells, are isolated directly from environmental sources and cultured using chemical factors from their native environment.Type: GrantFiled: March 27, 2013Date of Patent: April 21, 2020Assignee: Northeastern UniversityInventors: Edgar Daniel Goluch, Yoshiteru Aoi, Slava Epstein
-
Patent number: 10626436Abstract: A method of determining variation between a query cell culture media and a reference cell culture media is provided. The method comprises the steps of incubating a reference cell with an aliquot of the query culture media and at least three chemical cell stressors in wells of a microtitre plate and determining an environmental response of the reference cell in the presence of the query cell culture media and each of the plurality of chemical cell stressors. A query cell culture media specific environmental response fingerprint is generated comprising the plurality of chemical cell stressor specific environmental responses. The query cell culture media-specific environmental response fingerprint is compared with a reference media-specific environmental response fingerprints corresponding to a reference cell culture media and generated using the reference cell.Type: GrantFiled: April 1, 2016Date of Patent: April 21, 2020Assignee: Valitacell LimitedInventors: Jerry Clifford, David James, Ben Thompson
-
Patent number: 10626437Abstract: The present invention is directed to a method and kit for inactivation of acid-fast bacteria. In some embodiments, the method may include: transferring a sample from a liquid culture containing acid-fast bacteria to a first tube, wherein the first tube comprises a body, a first end to the body having an opening, and a second end to the body having a frustoconical portion ending in a concave tip; centrifuging the tube to pellet the acid-fast bacteria in the concave tip and subsequently decanting a supernatant; resuspending the acid-fast bacteria pellet in alcohol; transferring the suspension to a second tube containing beads; agitating the second tube to disrupt acid-fast bacteria cells; and incubating the suspension to inactivate the acid-fast bacteria in the test sample. The method may also include identifying the acid-fast bacteria with mass spectrometry.Type: GrantFiled: July 15, 2016Date of Patent: April 21, 2020Assignee: bioMerieux, Inc.Inventors: Parampal Deol, Eric Miller, Erik Moreno, Heather Totty
-
Patent number: 10626438Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).Type: GrantFiled: December 5, 2017Date of Patent: April 21, 2020Assignee: The Broad Institute, Inc.Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
-
Patent number: 10626439Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.Type: GrantFiled: March 14, 2014Date of Patent: April 21, 2020Assignee: Translate Bio, Inc.Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
-
Patent number: 10626440Abstract: A sequencer pretreatment device includes a suction and discharge mechanism, a nozzle head having a nozzle for mounting a dispensing tip, a container group for accommodating liquids including magnetic particle suspension, a moving mechanism for causing relative movement between the nozzle and the container group, and a magnetic unit that exerts a magnetic field to the mounted dispensing tip.Type: GrantFiled: May 21, 2014Date of Patent: April 21, 2020Assignee: UNIVERSAL BIO RESEARCH CO., LTD.Inventor: Hideji Tajima
-
Patent number: 10626441Abstract: Described herein is a method for adding a counter sequence to the individual polynucleotide molecules of an initial nucleic acid sample. After addition of the counter sequence, the sample may be amplified and the number of initial target molecules in the sample can be estimated by counting the number of counter sequences associated with the amplified target molecules.Type: GrantFiled: April 27, 2017Date of Patent: April 21, 2020Assignee: Agilent Technologies, Inc.Inventors: Robert Osborne, James Casbon, Andreas Claas, Gi Mikawa, Esther Musgrave-Brown
-
Patent number: 10626442Abstract: The invention provides methods, compositions, kits and devices for the detection of target molecules. In some embodiments, the invention allows for multiplexed target molecule detection.Type: GrantFiled: May 17, 2017Date of Patent: April 21, 2020Assignee: Roche Sequencing Solutions, Inc.Inventor: Garry P. Nolan